Influence of cefozopran on intestinal bacterial flora

S. Iwata, K. Kawahara, E. Isohata, Y. Kin, T. Yokota, Y. Kusumoto, Y. Sato, H. Akita, S. Nanri, T. Oikawa, K. Sunakawa

Research output: Contribution to journalArticle

Abstract

Cefozopran (CZOP, SCE-2787), a new parenteral cephalosporin antibiotic, was studied for its effect on the intestinal bacterial flora of pediatric patients. The subjects were children admitted for infections (6 males, 4 months to 3 years 2 months old, weight 5.6 to 19.0 kg). CZOP was intravenously administered at a dose from 19.8 to 52.6 mg/kg, 3 to 4 times daily. The feces from these children were collected before, during and after administration, and bacteria were identified and counted. The CZOP concentration, β-lactamase activity and Clostridium difficile D-1 antigen were also assayed, and the MICs of various isolated bacteria were measured. Changes of bacterial flora in feces during CZOP administration showed some variation. Among aerobic bacteria, 5 of the 6 cases showed a decrease in Enterobacteriaceae, but no significant change was observed in Enterococcus, and as a result, the total count of aerobic bacteria did not show a large change. Regarding anaerobic bacteria, no significant change was observed in Bifidobacterium or Bacteroides, and the total count of anaerobic bacteria did not show a large change. In no case, were glucose non-fermentative Gram-negative bacilli or fungi dominant. Although C. difficile and C. difficile D-1 antigen were detected in 2 and all cases, respectively, there was no clear relationship between the number of C. difficile and the characteristics of the feces. CZOP was detected in fecal samples from 4 cases during and after administration at concentrations ranging from 1.4 to 29.6 μg/g. Drug sensitivities of the bacteria isolated from feces did not change before, during and after the administration of CZOP. The above results suggest that CZOP is a drug with an extremely small influence on the intestinal bacterial flora of children among the new parenteral cephalosporin antibiotics.

Original languageEnglish
Pages (from-to)1021-1035
Number of pages15
JournalChemotherapy
Volume42
Issue number9
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Clostridium difficile
Feces
Aerobic Bacteria
Anaerobic Bacteria
Cephalosporins
Bacteria
cefozopran
Gastrointestinal Microbiome
Antigens
Bacteroides
Bifidobacterium
Enterococcus
Enterobacteriaceae
Pharmaceutical Preparations
Bacillus
Fungi
Pediatrics
Weights and Measures
Glucose
Infection

ASJC Scopus subject areas

  • Pharmacology

Cite this

Iwata, S., Kawahara, K., Isohata, E., Kin, Y., Yokota, T., Kusumoto, Y., ... Sunakawa, K. (1994). Influence of cefozopran on intestinal bacterial flora. Chemotherapy, 42(9), 1021-1035.

Influence of cefozopran on intestinal bacterial flora. / Iwata, S.; Kawahara, K.; Isohata, E.; Kin, Y.; Yokota, T.; Kusumoto, Y.; Sato, Y.; Akita, H.; Nanri, S.; Oikawa, T.; Sunakawa, K.

In: Chemotherapy, Vol. 42, No. 9, 1994, p. 1021-1035.

Research output: Contribution to journalArticle

Iwata, S, Kawahara, K, Isohata, E, Kin, Y, Yokota, T, Kusumoto, Y, Sato, Y, Akita, H, Nanri, S, Oikawa, T & Sunakawa, K 1994, 'Influence of cefozopran on intestinal bacterial flora', Chemotherapy, vol. 42, no. 9, pp. 1021-1035.
Iwata S, Kawahara K, Isohata E, Kin Y, Yokota T, Kusumoto Y et al. Influence of cefozopran on intestinal bacterial flora. Chemotherapy. 1994;42(9):1021-1035.
Iwata, S. ; Kawahara, K. ; Isohata, E. ; Kin, Y. ; Yokota, T. ; Kusumoto, Y. ; Sato, Y. ; Akita, H. ; Nanri, S. ; Oikawa, T. ; Sunakawa, K. / Influence of cefozopran on intestinal bacterial flora. In: Chemotherapy. 1994 ; Vol. 42, No. 9. pp. 1021-1035.
@article{5cece001add044e082c036e2c1f73914,
title = "Influence of cefozopran on intestinal bacterial flora",
abstract = "Cefozopran (CZOP, SCE-2787), a new parenteral cephalosporin antibiotic, was studied for its effect on the intestinal bacterial flora of pediatric patients. The subjects were children admitted for infections (6 males, 4 months to 3 years 2 months old, weight 5.6 to 19.0 kg). CZOP was intravenously administered at a dose from 19.8 to 52.6 mg/kg, 3 to 4 times daily. The feces from these children were collected before, during and after administration, and bacteria were identified and counted. The CZOP concentration, β-lactamase activity and Clostridium difficile D-1 antigen were also assayed, and the MICs of various isolated bacteria were measured. Changes of bacterial flora in feces during CZOP administration showed some variation. Among aerobic bacteria, 5 of the 6 cases showed a decrease in Enterobacteriaceae, but no significant change was observed in Enterococcus, and as a result, the total count of aerobic bacteria did not show a large change. Regarding anaerobic bacteria, no significant change was observed in Bifidobacterium or Bacteroides, and the total count of anaerobic bacteria did not show a large change. In no case, were glucose non-fermentative Gram-negative bacilli or fungi dominant. Although C. difficile and C. difficile D-1 antigen were detected in 2 and all cases, respectively, there was no clear relationship between the number of C. difficile and the characteristics of the feces. CZOP was detected in fecal samples from 4 cases during and after administration at concentrations ranging from 1.4 to 29.6 μg/g. Drug sensitivities of the bacteria isolated from feces did not change before, during and after the administration of CZOP. The above results suggest that CZOP is a drug with an extremely small influence on the intestinal bacterial flora of children among the new parenteral cephalosporin antibiotics.",
author = "S. Iwata and K. Kawahara and E. Isohata and Y. Kin and T. Yokota and Y. Kusumoto and Y. Sato and H. Akita and S. Nanri and T. Oikawa and K. Sunakawa",
year = "1994",
language = "English",
volume = "42",
pages = "1021--1035",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "9",

}

TY - JOUR

T1 - Influence of cefozopran on intestinal bacterial flora

AU - Iwata, S.

AU - Kawahara, K.

AU - Isohata, E.

AU - Kin, Y.

AU - Yokota, T.

AU - Kusumoto, Y.

AU - Sato, Y.

AU - Akita, H.

AU - Nanri, S.

AU - Oikawa, T.

AU - Sunakawa, K.

PY - 1994

Y1 - 1994

N2 - Cefozopran (CZOP, SCE-2787), a new parenteral cephalosporin antibiotic, was studied for its effect on the intestinal bacterial flora of pediatric patients. The subjects were children admitted for infections (6 males, 4 months to 3 years 2 months old, weight 5.6 to 19.0 kg). CZOP was intravenously administered at a dose from 19.8 to 52.6 mg/kg, 3 to 4 times daily. The feces from these children were collected before, during and after administration, and bacteria were identified and counted. The CZOP concentration, β-lactamase activity and Clostridium difficile D-1 antigen were also assayed, and the MICs of various isolated bacteria were measured. Changes of bacterial flora in feces during CZOP administration showed some variation. Among aerobic bacteria, 5 of the 6 cases showed a decrease in Enterobacteriaceae, but no significant change was observed in Enterococcus, and as a result, the total count of aerobic bacteria did not show a large change. Regarding anaerobic bacteria, no significant change was observed in Bifidobacterium or Bacteroides, and the total count of anaerobic bacteria did not show a large change. In no case, were glucose non-fermentative Gram-negative bacilli or fungi dominant. Although C. difficile and C. difficile D-1 antigen were detected in 2 and all cases, respectively, there was no clear relationship between the number of C. difficile and the characteristics of the feces. CZOP was detected in fecal samples from 4 cases during and after administration at concentrations ranging from 1.4 to 29.6 μg/g. Drug sensitivities of the bacteria isolated from feces did not change before, during and after the administration of CZOP. The above results suggest that CZOP is a drug with an extremely small influence on the intestinal bacterial flora of children among the new parenteral cephalosporin antibiotics.

AB - Cefozopran (CZOP, SCE-2787), a new parenteral cephalosporin antibiotic, was studied for its effect on the intestinal bacterial flora of pediatric patients. The subjects were children admitted for infections (6 males, 4 months to 3 years 2 months old, weight 5.6 to 19.0 kg). CZOP was intravenously administered at a dose from 19.8 to 52.6 mg/kg, 3 to 4 times daily. The feces from these children were collected before, during and after administration, and bacteria were identified and counted. The CZOP concentration, β-lactamase activity and Clostridium difficile D-1 antigen were also assayed, and the MICs of various isolated bacteria were measured. Changes of bacterial flora in feces during CZOP administration showed some variation. Among aerobic bacteria, 5 of the 6 cases showed a decrease in Enterobacteriaceae, but no significant change was observed in Enterococcus, and as a result, the total count of aerobic bacteria did not show a large change. Regarding anaerobic bacteria, no significant change was observed in Bifidobacterium or Bacteroides, and the total count of anaerobic bacteria did not show a large change. In no case, were glucose non-fermentative Gram-negative bacilli or fungi dominant. Although C. difficile and C. difficile D-1 antigen were detected in 2 and all cases, respectively, there was no clear relationship between the number of C. difficile and the characteristics of the feces. CZOP was detected in fecal samples from 4 cases during and after administration at concentrations ranging from 1.4 to 29.6 μg/g. Drug sensitivities of the bacteria isolated from feces did not change before, during and after the administration of CZOP. The above results suggest that CZOP is a drug with an extremely small influence on the intestinal bacterial flora of children among the new parenteral cephalosporin antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=0027944545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027944545&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027944545

VL - 42

SP - 1021

EP - 1035

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - 9

ER -